NAD+ and Longevity: What David Sinclair, Harvard Research, and the Science Actually Found

No scientist has done more to bring NAD+ into mainstream awareness than Professor David Sinclair of Harvard Medical School. His research, his book Lifespan, and his public advocacy for NAD+ precursors as a longevity intervention have sparked a global conversation about whether we can genuinely slow — or even reverse — aspects of biological ageing.

But what did the research actually find? And how do the scientific findings translate into practical, evidence-based action? This article separates the verified science from the enthusiasm, reviews the key Harvard and international longevity research, and explains what it means for anyone serious about NAD+ therapy.

Who Is David Sinclair and Why Does His Work Matter?

David Sinclair is Professor of Genetics at Harvard Medical School and co-Director of the Paul F. Glenn Center for Biology of Aging Research. He is one of the world's most cited researchers in the field of ageing biology, and his laboratory has published foundational work on sirtuins, NAD+, and the mechanisms of biological ageing.

His 2019 book Lifespan: Why We Age and Why We Don't Have To brought the concept of information theory of ageing — and NAD+'s central role in it — to a broad public audience. Since its publication, the scientific and wellness communities have scrutinised both the evidence base and the conclusions drawn from it.

The Core Scientific Findings from Sinclair's Laboratory

NAD+ and Sirtuin Activation: The Foundation

Sinclair's laboratory has produced some of the most influential work on sirtuins — the NAD+-dependent proteins often described as longevity regulators. Key findings from his group include:

•       Sirtuins require NAD+ as a co-substrate to perform their deacetylase function. Without adequate NAD+, sirtuins are essentially switched off, regardless of their expression level.

•       SIRT1, the most studied sirtuin, regulates a remarkable range of biological processes including DNA repair, inflammation, metabolism, circadian rhythm, and mitochondrial biogenesis.

•       In animal models, increasing NAD+ availability — either through genetic manipulation or supplementation — activates sirtuins and produces measurable improvements in health and longevity markers.

The 2013 Landmark Mouse Study

A 2013 paper from the Sinclair laboratory published in Cell reported that administering NMN to aged mice (equivalent to a 60-year-old human) produced muscle tissue that was indistinguishable from that of young mice within one week. Mitochondrial function improved dramatically, and the researchers identified NAD+ depletion and the resulting decline in SIRT1 activity as the primary mechanism of the age-related deterioration they observed.

This study was widely reported as evidence that ageing could be 'reversed' — a characterisation that Sinclair himself has cautioned requires nuance. What the study demonstrated more precisely was that a specific age-related change in muscle mitochondrial function was reversible through NAD+ restoration. Extrapolating this to human ageing broadly requires further evidence.

The Information Theory of Ageing

Sinclair's broader theoretical framework — the Information Theory of Ageing — proposes that ageing is fundamentally a loss of epigenetic information: the instructions that tell cells what type they are and how to behave. NAD+ features centrally in this model because the sirtuins that help maintain and restore this epigenetic information are NAD+-dependent.

In this framework, maintaining or restoring NAD+ levels is not merely about energy — it is about preserving the fidelity of the cellular information systems that keep you healthy and young. This is the intellectual foundation of much of the enthusiasm for NAD+ therapy in the longevity community.

NADvance delivers pharmaceutical-grade NAD+ subcutaneously — the same molecule at the centre of Sinclair's research, produced to MHRA-approved, GMP-certified standards. Explore at nadvance.eu/pages/pen

What Other Research Institutions Have Found

The Salk Institute

Researchers at the Salk Institute for Biological Studies have published work showing that NAD+ supplementation in aged animal models improves stem cell function, reduces inflammation, and enhances metabolic health — findings that converge with Sinclair's mechanistic work from a different angle.

Washington University School of Medicine

A 2021 clinical trial from Washington University demonstrated that NMN supplementation improved muscle insulin sensitivity and aerobic capacity in postmenopausal women — a human translation of findings from animal model research and one of the strongest human clinical data points to date.

Keio University, Japan

Japanese researchers at Keio University School of Medicine published Phase I and II clinical trials on NMN showing safety and efficacy in raising blood NAD+ levels in older adults, with improvements in physical function at 12 weeks. Japan has become one of the leading centres for human NAD+ clinical research.

The Sinclair Protocol: What He Actually Does

David Sinclair has publicly shared his own supplement protocol, which includes daily NMN at 1 gram, combined with resveratrol, metformin (by prescription), and other interventions. Several important notes:

•       Sinclair acknowledges that his own protocol is based on the best current evidence applied to his individual context — it is not a clinical prescription for others.

•       He has noted that the human trial data on NMN remains less robust than the animal model data, and that he is essentially running an experiment on himself.

•       He has not, to date, explicitly advocated for subcutaneous NAD+ injection as his preferred delivery method — though he acknowledges the bioavailability limitations of oral supplementation.

The broader scientific consensus among longevity researchers — including those outside Sinclair's group — is that injectable delivery of NAD+ consistently produces higher and more reliable plasma levels than oral precursors.

What This Means for Your NAD+ Decisions in 2026

The longevity research on NAD+ has produced a clear and consistent message across multiple independent research groups:

•       NAD+ is a fundamental cellular molecule whose decline with age is causally linked to the functional deterioration we recognise as ageing.

•       Restoring NAD+ levels produces meaningful biological improvements in multiple systems — energy, metabolism, cognition, physical function.

•       The delivery method matters: injectable routes achieve bioavailability that oral supplementation cannot match.

•       The science is strong and growing. This is not a fringe wellness claim — it is the direction of a significant and well-funded body of mainstream academic research.

Frequently Asked Questions

Q: What did David Sinclair's research actually prove about NAD+? A: Sinclair's laboratory demonstrated that NAD+ decline is a central driver of age-related mitochondrial dysfunction, and that restoring NAD+ levels — through supplementation in animal models — reverses these changes. His work established the mechanistic link between NAD+, sirtuin activation, and longevity pathways. Human clinical translation is ongoing and increasingly supportive.

 

Q: Is NAD+ therapy the same as what Sinclair researches? A: The NAD+ molecule is the same. Sinclair's animal research and the growing human clinical literature both involve elevating NAD+ levels to activate longevity pathways. The key variable is delivery method — injectable routes achieve more reliable plasma elevation than the oral NMN Sinclair personally uses.

 

Q: What does Harvard research say about NAD+ in humans? A: Harvard-affiliated research, including the Washington University trials Sinclair's group collaborates with, shows that NAD+ precursor supplementation elevates blood NAD+ levels and improves metabolic and physical function markers in human trials. The evidence base is growing steadily.

 

Q: Should I take NMN or NAD+ directly based on the research? A: The research suggests that direct NAD+ delivered via injection bypasses the conversion inefficiency that limits oral NMN's effectiveness — particularly in older adults where the conversion enzyme NAMPT becomes less active. For those serious about meaningful NAD+ restoration, injectable delivery is the evidence-supported choice.

Ready to apply the science to your own protocol? Visit nadvance.eu/products/nadvance-pen-1000mg to explore the NADvance pen — pharmaceutical-grade NAD+ for subcutaneous delivery.

Have clinical questions? Our FAQ at nadvance.eu/pages/faq provides detailed, science-backed answers. Usage guidance at nadvance.eu/pages/instructions.